Asghar Askari, MD
Urology · San Pedro
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 54 years
- Graduated 1972
Offices
1 location
Hospitals listed: Providence Little Company of Mary Med Ctr Torrance · Providence Little Co of Mary Med Ctr San Pedro. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Askari’s office at (310) 519-9100 to ask if they take your plan before you enroll.
California Medical Board record
Licence A35822 · Current
Licensed to practise in California · since 1980 · expires 2028-01-31 · National University of Iran Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Pacific Coast Surgical CenterAmbulatory Surgery Center · Torrance, CAOwner · accredited by JCDenied Accreditation1 inspection, 1 with deficiencies · last 2014-03-17: Requirements Met
- Pacific Coast Surgical Center, LPAmbulatory Surgery Center · Torrance, CA2% owner since 2008 · accredited by AAAHCAccreditation Renewed5 inspections, 4 with deficiencies · last 2024-09-10: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Surgery - Surgery
- American Board of Urology - Female Pelvic Medicine and Reconstructive Surgery
- American Board of Urology - Pediatric Urology
- American Board of Urology - Urology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Providence Little Co of Mary Med Ctr San PedroSan Pedro, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency departmentPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Providence Little Company of Mary Med Ctr TorranceTorrance, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.472, Oct 2024 – Sep 2025
See every measure and the patient survey for Providence Little Co of Mary Med Ctr San Pedro
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 2 the same, 0 worse of 3 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0 to 2.08) · 260 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.45 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.3 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.2 · 86 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.8 · 115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.2 · 46 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 844 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 1,991 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,930 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.21 (0.68 to 5.75) · 195 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.6 (0.89 to 4.31) · 181 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.82 (0 to 18.7) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.05 (0.78 to 9.31) · 47 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 53 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.35 (0 to 1.36) · 1,620 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 28 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.687 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 170 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2.2 · 103 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.6 · 126 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 182 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 25 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 52 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.3 to 17.3) · 120 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 56 cases | No different | Jan 2024 – Dec 2024 |
What patients said (414 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Providence Little Company of Mary Med Ctr Torrance
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.472 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.09 (0.11 to 2.07) · 1,022 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.59 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 129.31 (75.73 to 182.88) · 65 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.4 · 353 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 361 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 495 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 3,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 5,786 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.06 to 0.45) · 5,832 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.21 (2.1 to 6.32) · 1,135 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.81 (0.22 to 3.4) · 375 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.8 to 3.86) · 1,086 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.78 (2.28 to 15.28) · 389 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.58 (1.19 to 7.98) · 377 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2 (0.51 to 3.49) · 247 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 0.93) · 4,918 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.892 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.225 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.363 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 283 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 709 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 10.5 · 149 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.9 · 428 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13.8 · 369 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 551 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 59 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 168 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (8.9 to 15.5) · 642 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 331 cases | No different | Jan 2024 – Dec 2024 |
What patients said (414 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$105,061
Medicare paid this office $105,061 for 388 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 297 | $46,690 | $73 |
| Return visit (30+ min) | 60 | $6,661 | $101 |
| New patient visit (45+ min) | 43 | $5,546 | $129 |
| Diagnostic exam of bladder and urethra using an endoscope | 19 | $4,561 | $198 |
| Injection of drug or substance under skin or into muscle | 35 | $2,260 | $12 |
See all 10 services
| Short return visit (20+ min) | 297 | $46,690 | $73 |
| Return visit (30+ min) | 60 | $6,661 | $101 |
| New patient visit (45+ min) | 43 | $5,546 | $129 |
| Diagnostic exam of bladder and urethra using an endoscope | 19 | $4,561 | $198 |
| Injection of drug or substance under skin or into muscle | 35 | $2,260 | $12 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,129 | $142 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $1,370 | $30 |
| Electronic assessment of bladder emptying | 88 | $1,204 | $10 |
| Ultrasound measurement of bladder capacity after voiding | 99 | $1,184 | $9 |
| Injection, testosterone cypionate, 1 mg | 32 | $3 | None |
Procedures Medicare counted
| Prostate resection | 22 | More than 82% of doctors who do this |
| Removal of the uterus | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Ultrasound measurement of bladder capacity after voiding | 245 | 254 | 335 | 361 | 298 | 131 |
| Electronic assessment of bladder emptying | 249 | 236 | 319 | 314 | 267 | 117 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 62 | 138 | 160 | 131 | – | – |
| Diagnostic exam of bladder and urethra using an endoscope | 62 | 64 | 68 | 55 | 37 | 23 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 14 | 27 | 28 | 28 | – | – |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 14 | – | 27 | 14 | 12 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
388 Original Medicare patients in 2024. Average age 77 · Under 65 6% · 85 and older 21% · Women 21% · Also on Medicaid 25% · Health risk score 1.51. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 44% · Coronary heart disease 28% · Chronic kidney disease 28% · Cancer 21% · Atrial fibrillation 21% · Heart failure 19% · Depression 19% · COPD 14% · Stroke 10% · Dementia 8%.
The office billed $473,423, Medicare allowed $138,629 and paid $105,061; for 1,637 services of 51 kinds; $3,074 of it was for drugs given in the office and $101,987 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 388 | 1,637 | 77 | 1.51 | $473,423 | $105,061 |
| 2023 | 452 | 1,904 | 77 | 1.44 | $804,200 | $178,139 |
| 2022 | 429 | 2,412 | 77 | 1.31 | $1,110,203 | $243,086 |
| 2021 | 433 | 2,184 | 77 | 1.43 | $1,036,539 | $338,716 |
| 2020 | 451 | 1,973 | 76 | 1.40 | $674,172 | $231,808 |
| 2019 | 538 | 2,281 | 76 | 1.54 | $717,493 | $261,546 |
| 2018 | 426 | 1,731 | 75 | 1.43 | $498,858 | $151,858 |
| 2017 | 372 | 1,463 | 75 | 1.49 | $396,007 | $109,789 |
| 2016 | 343 | 1,305 | 75 | 1.61 | $347,282 | $103,863 |
| 2015 | 395 | 1,416 | 74 | 1.67 | $444,859 | $135,655 |
| 2014 | 452 | 1,780 | 73 | 1.60 | $487,251 | $139,043 |
| 2013 | 481 | 1,800 | 73 | 1.69 | $547,686 | $152,872 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Short return visit (20+ min) | 295 | $51,716 | $71 |
| New patient visit (45+ min) | 64 | $7,993 | $125 |
| Diagnostic exam of bladder and urethra using an endoscope | 34 | $7,880 | $213 |
| Return visit (30+ min) | 57 | $7,162 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $4,717 | $143 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 12 | $3,622 | $302 |
| Electronic assessment of bladder emptying | 152 | $2,871 | $11 |
| Ultrasound measurement of bladder capacity after voiding | 167 | $2,637 | $9 |
| Insertion of device into abdomen with pressure and urine flow rate study | 15 | $2,581 | $172 |
| Biopsy of prostate gland | 13 | $2,568 | $198 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 26 | $1,943 | $41 |
| Ultrasound scan of pelvic region through rectum | 14 | $1,892 | $118 |
2022: 18 services
| Short return visit (20+ min) | 307 | $68,000 | $75 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 11 | $55,041 | $860 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 11 | $13,256 | $1,205 |
| Diagnostic exam of bladder and urethra using an endoscope | 53 | $11,818 | $215 |
| New patient visit (45+ min) | 75 | $10,565 | $141 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 42 | $9,978 | $232 |
| Return visit (30+ min) | 64 | $7,608 | $106 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 14 | $4,787 | $342 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,683 | $167 |
| Insertion of device into abdomen with pressure and urine flow rate study | 20 | $3,718 | $186 |
| Electronic assessment of bladder emptying | 169 | $3,351 | $11 |
| Ultrasound measurement of bladder capacity after voiding | 182 | $3,243 | $9 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 17 | $3,000 | $176 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 13 | $2,830 | $42 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 38 | $2,111 | $32 |
| Ultrasound scan of pelvic region through rectum | 13 | $1,610 | $124 |
| New patient visit (30+ min) | 14 | $1,179 | $84 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 25 | $808 | $29 |
2021: 15 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 28 | $152,739 | $955 |
| Short return visit (20+ min) | 306 | $57,742 | $71 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 28 | $37,018 | $1,322 |
| Diagnostic exam of bladder and urethra using an endoscope | 59 | $14,335 | $211 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 27 | $9,965 | $369 |
| Exam of bladder and urethra for treatment of female urethral syndrome using an endoscope | 16 | $5,663 | $283 |
| New patient visit (45+ min) | 39 | $5,422 | $139 |
| Electronic assessment of bladder emptying | 167 | $3,500 | $11 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,426 | $171 |
| New patient visit (30+ min) | 37 | $3,354 | $91 |
| Return visit (30+ min) | 31 | $3,289 | $103 |
| Ultrasound measurement of bladder capacity after voiding | 178 | $2,973 | $9 |
| Ultrasound scan of pelvic region through rectum | 13 | $1,572 | $121 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $754 | $33 |
| Urinalysis, manual test | 22 | $77 | $3 |
2020: 18 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 14 | $70,743 | $943 |
| Short return visit (20+ min) | 304 | $39,883 | $53 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 14 | $17,822 | $1,273 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $14,219 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 53 | $11,986 | $187 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,638 | $171 |
| New patient visit (30+ min) | 62 | $5,454 | $88 |
| Ultrasound scan of pelvic region through rectum | 28 | $3,885 | $134 |
| Exam of bladder and urethra for treatment of female urethral syndrome using an endoscope | 13 | $3,825 | $273 |
| New patient visit (45+ min) | 25 | $3,613 | $145 |
| Biopsy of prostate gland | 15 | $3,380 | $225 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 13 | $2,784 | $44 |
| Electronic assessment of bladder emptying | 145 | $2,605 | $11 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 13 | $2,315 | $178 |
| Return visit (30+ min) | 24 | $2,226 | $82 |
| Ultrasound measurement of bladder capacity after voiding | 158 | $2,178 | $9 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $1,119 | $34 |
| Urinalysis, manual test | 25 | $90 | $3 |
2019: 20 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 12 | $54,433 | $878 |
| Short return visit (20+ min) | 376 | $51,418 | $55 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 14 | $16,506 | $1,179 |
| New patient visit (30+ min) | 194 | $15,576 | $80 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 21 | $14,259 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 55 | $10,180 | $164 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $9,799 | $169 |
| Shock wave crushing of kidney stones | 15 | $8,435 | $496 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 13 | $7,807 | $601 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 14 | $4,566 | $326 |
| Biopsy of prostate gland | 18 | $4,029 | $224 |
| Ultrasound scan of pelvic region through rectum | 31 | $3,640 | $117 |
| Exam of bladder and urethra for treatment of female urethral syndrome using an endoscope | 16 | $3,498 | $206 |
| Insertion of stent in ureter using an endoscope | 21 | $2,899 | $132 |
| Electronic assessment of bladder emptying | 164 | $2,732 | $11 |
| Return visit (30+ min) | 31 | $2,699 | $84 |
| Ultrasound measurement of bladder capacity after voiding | 166 | $2,557 | $10 |
| New patient visit (45+ min) | 14 | $1,990 | $142 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 21 | $1,065 | $33 |
| Urinalysis, manual test | 17 | $61 | $3 |
2018: 17 services
| Short return visit (20+ min) | 275 | $43,340 | $53 |
| Destruction of prostate tissue using microwave induced heat | 13 | $24,279 | $1,868 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 21 | $12,189 | $580 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $8,030 | $167 |
| New patient visit (30+ min) | 87 | $7,611 | $87 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $5,466 | None |
| Shock wave crushing of kidney stones | 11 | $5,310 | $483 |
| Diagnostic exam of bladder and urethra using an endoscope | 36 | $4,503 | $122 |
| Return visit (30+ min) | 52 | $4,262 | $75 |
| Biopsy of prostate gland | 11 | $2,610 | $218 |
| Ultrasound measurement of bladder capacity after voiding | 133 | $2,602 | $14 |
| Electronic assessment of bladder emptying | 123 | $2,227 | $13 |
| Exam of bladder and urethra for treatment of female urethral syndrome using an endoscope | 11 | $2,171 | $197 |
| New patient visit (45+ min) | 13 | $1,797 | $138 |
| Ultrasound scan of pelvic region through rectum | 12 | $1,115 | $86 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $935 | $32 |
| Urinalysis, manual test | 16 | $55 | $3 |
2017: 14 services
| Short return visit (20+ min) | 239 | $36,898 | $53 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 22 | $12,653 | $575 |
| Return visit (30+ min) | 63 | $5,127 | $78 |
| New patient visit (30+ min) | 64 | $5,012 | $78 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 13 | $3,623 | $279 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,129 | $165 |
| Diagnostic exam of bladder and urethra using an endoscope | 24 | $3,087 | $123 |
| Exam of bladder and urethra for treatment of female urethral syndrome using an endoscope | 15 | $2,846 | $178 |
| Ultrasound measurement of bladder capacity after voiding | 121 | $2,585 | $16 |
| Electronic assessment of bladder emptying | 108 | $1,861 | $12 |
| Long return visit (40+ min) | 18 | $1,666 | $93 |
| Insertion of device into abdomen with pressure and urine flow rate study | 11 | $1,079 | $98 |
| Insertion of temporary bladder tube | 12 | $775 | $41 |
| Urinalysis, manual test | 30 | $103 | $3 |
2016: 14 services
| Short return visit (20+ min) | 252 | $33,499 | $53 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 21 | $12,308 | $586 |
| New patient visit (30+ min) | 79 | $6,816 | $86 |
| Diagnostic exam of bladder and urethra using an endoscope | 32 | $5,190 | $148 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 16 | $4,759 | $297 |
| Return visit (30+ min) | 57 | $3,999 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,702 | $168 |
| Biopsy of prostate gland | 12 | $2,439 | $188 |
| Ultrasound measurement of bladder capacity after voiding | 80 | $1,591 | $16 |
| Insertion of device into abdomen with pressure and urine flow rate study | 14 | $1,371 | $98 |
| Long return visit (40+ min) | 15 | $1,215 | $81 |
| Electronic assessment of bladder emptying | 71 | $1,131 | $12 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $816 | $31 |
| Urinalysis, manual test | 20 | $75 | $3 |
2015: 16 services
| Short return visit (20+ min) | 253 | $31,624 | $52 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 18 | $10,453 | $581 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 25 | $7,262 | $290 |
| Diagnostic exam of bladder and urethra using an endoscope | 41 | $6,867 | $149 |
| Return visit (30+ min) | 82 | $5,978 | $64 |
| New patient visit (30+ min) | 52 | $4,242 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,861 | $168 |
| Exam of bladder and urethra for treatment of female urethral syndrome using an endoscope | 15 | $2,538 | $159 |
| Insertion of device into abdomen with pressure and urine flow rate study | 21 | $2,081 | $99 |
| Insertion of stent in ureter using an endoscope | 11 | $1,731 | $124 |
| Ultrasound measurement of bladder capacity after voiding | 75 | $1,534 | $16 |
| Ultrasound scan of pelvic region through rectum | 17 | $1,408 | $78 |
| Long return visit (40+ min) | 13 | $1,078 | $83 |
| Electronic assessment of bladder emptying | 68 | $984 | $11 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $917 | $33 |
| Urinalysis, manual test | 30 | $119 | $3 |
2014: 23 services
| Short return visit (20+ min) | 256 | $28,809 | $52 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 24 | $13,938 | $581 |
| Insertion of lower leg neurostimulator electrode | 13 | $9,779 | $104 |
| Diagnostic exam of bladder and urethra using an endoscope | 54 | $8,933 | $162 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $6,831 | None |
| New patient visit (30+ min) | 71 | $5,348 | $75 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 14 | $4,081 | $291 |
| Biopsy of prostate gland | 18 | $3,371 | $187 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,226 | $170 |
| Ultrasound measurement of bladder capacity after voiding | 146 | $3,121 | $15 |
| Return visit (30+ min) | 45 | $2,990 | $59 |
| Exam of bladder and urethra for treatment of female urethral syndrome using an endoscope | 15 | $2,616 | $174 |
| Short return visit (20+ min) | 39 | $2,446 | $42 |
| Electronic assessment of bladder emptying | 129 | $2,173 | $12 |
| Ultrasound scan of pelvic region through rectum | 25 | $2,044 | $82 |
| Diagnostic exam of bladder and urethra using an endoscope | 11 | $1,393 | $107 |
| Insertion of device into abdomen with pressure and urine flow rate study | 13 | $1,273 | $98 |
| Ultrasonic guidance for needle placement | 19 | $1,227 | $65 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $1,100 | $28 |
| Long return visit (40+ min) | 11 | $882 | $80 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $819 | $33 |
| Short return visit | 23 | $528 | $20 |
| Urinalysis, manual test | 31 | $147 | $3 |
2013: 18 services
| Short return visit (20+ min) | 261 | $27,614 | $53 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 28 | $15,678 | $560 |
| Diagnostic exam of bladder and urethra using an endoscope | 59 | $10,978 | $164 |
| New patient visit (30+ min) | 81 | $6,402 | $79 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,099 | $164 |
| Ultrasonic guidance for needle placement | 20 | $3,348 | $159 |
| Ultrasound measurement of bladder capacity after voiding | 147 | $3,344 | $16 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 12 | $3,285 | $274 |
| Biopsy of prostate gland | 19 | $3,179 | $167 |
| Return visit (30+ min) | 42 | $2,800 | $62 |
| Short return visit (20+ min) | 52 | $2,180 | $36 |
| Exam of bladder and urethra for treatment of female urethral syndrome using an endoscope | 12 | $2,114 | $176 |
| Diagnostic exam of bladder and urethra using an endoscope | 21 | $2,068 | $98 |
| Electronic assessment of bladder emptying | 121 | $2,058 | $11 |
| Ultrasound scan of pelvic region through rectum | 26 | $1,694 | $61 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 27 | $1,521 | $32 |
| Short return visit | 25 | $525 | $18 |
| Urinalysis, manual test | 66 | $285 | $3 |
Medicaid work
$1,760 in 2024
Medicaid paid $1,760 for 143 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 103 | $1,040 |
| New patient visit (45+ min) | 40 | $720 |
| 2024 | 143 | 2 | 22 | $1,760 |
| 2023 | 93 | 1 | 17 | $1,023 |
| 2022 | 128 | 2 | 17 | $3,859 |
| 2021 | 103 | 1 | 16 | $1,655 |
| 2019 | 16 | 1 | 14 | $300 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 93 | $1,023 |
2022
| Short return visit (20+ min) | 116 | $3,122 |
| New patient visit (45+ min) | 12 | $737 |
2021
| Short return visit (20+ min) | 103 | $1,655 |
2019
| Short return visit (20+ min) | 16 | $300 |
Drugs they prescribed that Part D paid
$559,840
Pharmacies billed $559,840 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (76 of 2,723) in 2024. Above the middle of the specialty; the typical urology clinician is at 2%.
2,502 generic and fewer than 11 brand-name prescriptions · $559,840 in drug cost · 553 antibiotic prescriptions to 257 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 27 | $372,034 | $13,779 |
| Gemtesa | 74 | $59,731 | $807 |
| Myrbetriq | 88 | $53,112 | $604 |
| Tamsulosin | 885 | $12,708 | $14 |
| Testosterone | 46 | $7,688 | $167 |
See all 25 drugs
| Xtandi | 27 | $372,034 | $13,779 |
| Gemtesa | 74 | $59,731 | $807 |
| Myrbetriq | 88 | $53,112 | $604 |
| Tamsulosin | 885 | $12,708 | $14 |
| Testosterone | 46 | $7,688 | $167 |
| Dutasteride | 204 | $5,982 | $29 |
| Methenamine Hippurate | 61 | $4,396 | $72 |
| Alfuzosin Hcl Er | 191 | $4,093 | $21 |
| Tadalafil | 16 | $4,086 | $255 |
| Bethanechol Chloride | 43 | $2,969 | $69 |
| Potassium Citrate Er | 34 | $2,431 | $72 |
| Nitrofurantoin Mono-Macro | 100 | $2,380 | $24 |
| Fesoterodine Fumarate Er | 31 | $1,539 | $50 |
| Ciprofloxacin | 293 | $1,219 | $4 |
| Solifenacin | 29 | $1,142 | $39 |
| Finasteride | 102 | $955 | $9 |
| Cefuroxime | 76 | $862 | $11 |
| Bicalutamide | 24 | $551 | $23 |
| Sulfamethoxazole-Trimethoprim | 46 | $413 | $9 |
| Testosterone Cypionate | 11 | $321 | $29 |
| Oxybutynin Chloride Er | 18 | $204 | $11 |
| Allopurinol | 11 | $162 | $15 |
| Tramadol | 65 | $96 | $1 |
| Ibuprofen | 30 | $53 | $2 |
| Meloxicam | 11 | $13 | $1 |
Year by year
| 2024 | 2,723 | 530 | 3% (76) | None | $559,840 |
| 2023 | 2,440 | 491 | 3% (63) | None | $506,827 |
| 2022 | 2,576 | 494 | 3% (65) | None | $279,732 |
| 2021 | 2,779 | 573 | 4% (104) | 9% | $385,635 |
| 2020 | 3,556 | 728 | 3% (107) | None | $763,444 |
| 2019 | 3,497 | 773 | 3% (120) | 14% | $674,838 |
| 2018 | 2,652 | 606 | 3% (69) | None | $272,399 |
| 2017 | 1,998 | 448 | 4% (75) | 14% | $233,458 |
| 2016 | 1,944 | 429 | 5% (93) | None | $136,668 |
| 2015 | 1,983 | 397 | 2% (47) | 22% | $151,454 |
| 2014 | 1,954 | 408 | 3% (49) | 30% | $167,728 |
| 2013 | 2,053 | 392 | 4% (74) | 30% | $185,049 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Xtandi | 20 | $301,377 | $15,069 |
| Myrbetriq | 81 | $55,840 | $689 |
| Gemtesa | 32 | $24,450 | $764 |
| Tamsulosin | 801 | $18,353 | $23 |
| Dutasteride | 198 | $14,441 | $73 |
| Alfuzosin Hcl Er | 177 | $7,843 | $44 |
| Bethanechol Chloride | 64 | $4,806 | $75 |
| Fesoterodine Fumarate Er | 44 | $4,300 | $98 |
| Potassium Citrate Er | 38 | $4,182 | $110 |
| Nitrofurantoin Mono-Macro | 96 | $3,600 | $38 |
| Methenamine Hippurate | 30 | $3,274 | $109 |
| Finasteride | 99 | $2,271 | $23 |
| Tadalafil | 20 | $1,977 | $99 |
| Solifenacin | 21 | $1,684 | $80 |
| Ciprofloxacin | 217 | $1,347 | $6 |
| Cefuroxime | 64 | $1,142 | $18 |
| Testosterone | 12 | $1,134 | $94 |
| Oxybutynin Chloride Er | 14 | $576 | $41 |
| Bicalutamide | 25 | $523 | $21 |
| Sulfamethoxazole-Trimethoprim | 47 | $457 | $10 |
| Terazosin | 11 | $256 | $23 |
| Tramadol | 47 | $138 | $3 |
| Meloxicam | 11 | $137 | $12 |
| Levofloxacin | 15 | $137 | $9 |
| Zolpidem | 11 | $48 | $4 |
| Ibuprofen | 16 | $32 | $2 |
2022: 28 drugs
| Myrbetriq | 87 | $52,526 | $604 |
| Dutasteride | 224 | $16,584 | $74 |
| Tamsulosin | 801 | $14,814 | $18 |
| Toviaz | 18 | $10,273 | $571 |
| Alfuzosin Hcl Er | 195 | $7,873 | $40 |
| Nitrofurantoin Mono-Macro | 102 | $5,311 | $52 |
| Bethanechol Chloride | 94 | $4,801 | $51 |
| Potassium Citrate Er | 30 | $2,490 | $83 |
| Betamethasone Dipropionate | 12 | $2,270 | $189 |
| Fesoterodine Fumarate Er | 16 | $2,236 | $140 |
| Cefuroxime | 98 | $2,083 | $21 |
| Finasteride | 110 | $1,917 | $17 |
| Testosterone | 11 | $1,908 | $173 |
| Solifenacin | 20 | $1,204 | $60 |
| Ciprofloxacin | 216 | $919 | $4 |
| Bicalutamide | 28 | $810 | $29 |
| Oxybutynin Chloride Er | 18 | $621 | $35 |
| Rosuvastatin | 21 | $456 | $22 |
| Sulfamethoxazole-Trimethoprim | 58 | $348 | $6 |
| Pentoxifylline | 17 | $317 | $19 |
| Terazosin | 12 | $190 | $16 |
| Tramadol | 52 | $139 | $3 |
| Metformin | 11 | $103 | $9 |
| Hydrocodone-Acetaminophen | 12 | $59 | $5 |
| Pravastatin | 11 | $58 | $5 |
| Ibuprofen | 20 | $44 | $2 |
| Zolpidem | 13 | $39 | $3 |
| Meloxicam | 13 | $30 | $2 |
2021: 31 drugs
| Xtandi | 14 | $173,372 | $12,384 |
| Myrbetriq | 108 | $64,285 | $595 |
| Toviaz | 21 | $16,569 | $789 |
| Testosterone | 28 | $14,196 | $507 |
| Dutasteride | 193 | $12,662 | $66 |
| Tamsulosin | 780 | $12,530 | $16 |
| Alfuzosin Hcl Er | 229 | $9,106 | $40 |
| Tadalafil | 15 | $7,084 | $472 |
| Nitrofurantoin Mono-Macro | 99 | $5,431 | $55 |
| Bethanechol Chloride | 51 | $4,779 | $94 |
| Finasteride | 155 | $4,074 | $26 |
| Potassium Citrate Er | 38 | $3,171 | $83 |
| Oxybutynin Chloride Er | 49 | $2,715 | $55 |
| Solifenacin | 30 | $2,252 | $75 |
| Cefuroxime | 71 | $1,482 | $21 |
| Bicalutamide | 29 | $1,314 | $45 |
| Ciprofloxacin | 281 | $1,094 | $4 |
| Pentoxifylline | 22 | $556 | $25 |
| Testosterone Cypionate | 13 | $482 | $37 |
| Sulfamethoxazole-Trimethoprim | 43 | $267 | $6 |
| Hydrocodone-Acetaminophen | 51 | $245 | $5 |
| Oxybutynin Chloride | 18 | $225 | $13 |
| Amlodipine Besylate | 11 | $171 | $16 |
| Allopurinol | 16 | $165 | $10 |
| Tramadol | 52 | $154 | $3 |
| Terazosin | 12 | $137 | $11 |
| Phenazopyridine | 13 | $126 | $10 |
| Alprazolam | 12 | $89 | $7 |
| Ibuprofen | 50 | $76 | $2 |
| Zolpidem | 15 | $52 | $3 |
| Lorazepam | 23 | $22 | $1 |
2020: 32 drugs
| Xtandi | 34 | $371,883 | $10,938 |
| Myrbetriq | 167 | $93,121 | $558 |
| Lupron Depot | 32 | $79,037 | $2,470 |
| Toviaz | 48 | $32,792 | $683 |
| Testosterone | 24 | $24,341 | $1,014 |
| Dutasteride | 254 | $21,266 | $84 |
| Tamsulosin | 981 | $17,663 | $18 |
| Alfuzosin Hcl Er | 329 | $13,084 | $40 |
| Tadalafil | 20 | $12,947 | $647 |
| Nitrofurantoin Mono-Macro | 146 | $7,081 | $49 |
| Bethanechol Chloride | 51 | $5,602 | $110 |
| Finasteride | 221 | $5,187 | $23 |
| Oxybutynin Chloride Er | 76 | $4,176 | $55 |
| Silodosin | 21 | $3,582 | $171 |
| Potassium Citrate Er | 27 | $3,199 | $118 |
| Bicalutamide | 46 | $2,806 | $61 |
| Solifenacin | 20 | $2,328 | $116 |
| Betamethasone Dipropionate | 13 | $1,820 | $140 |
| Ciprofloxacin | 392 | $1,772 | $5 |
| Nystatin-Triamcinolone | 24 | $1,654 | $69 |
| Cefuroxime | 60 | $1,358 | $23 |
| Testosterone Cypionate | 23 | $1,118 | $49 |
| Oxybutynin Chloride | 22 | $684 | $31 |
| Tramadol | 77 | $337 | $4 |
| Allopurinol | 27 | $331 | $12 |
| Sulfamethoxazole-Trimethoprim | 50 | $264 | $5 |
| Amlodipine Besylate | 19 | $93 | $5 |
| Hydrocodone-Acetaminophen | 30 | $87 | $3 |
| Ibuprofen | 21 | $49 | $2 |
| Alprazolam | 11 | $39 | $4 |
| Hydrochlorothiazide | 14 | $30 | $2 |
| Lorazepam | 18 | $15 | $1 |
2019: 35 drugs
| Xtandi | 30 | $300,595 | $10,020 |
| Myrbetriq | 169 | $89,201 | $528 |
| Lupron Depot | 21 | $51,811 | $2,467 |
| Androgel | 11 | $46,481 | $4,226 |
| Toviaz | 72 | $41,035 | $570 |
| Tamsulosin | 883 | $17,226 | $20 |
| Dutasteride | 231 | $16,493 | $71 |
| Alfuzosin Hcl Er | 313 | $11,604 | $37 |
| Vesicare | 20 | $9,751 | $488 |
| Testosterone | 21 | $7,615 | $363 |
| Bethanechol Chloride | 62 | $7,095 | $114 |
| Tadalafil | 21 | $6,431 | $306 |
| Solifenacin | 22 | $5,925 | $269 |
| Nitrofurantoin Mono-Macro | 137 | $5,835 | $43 |
| Finasteride | 222 | $5,699 | $26 |
| Potassium Citrate Er | 32 | $4,508 | $141 |
| Silodosin | 26 | $4,043 | $156 |
| Oxybutynin Chloride Er | 52 | $3,401 | $65 |
| Ciprofloxacin | 444 | $3,038 | $7 |
| Bicalutamide | 56 | $2,319 | $41 |
| Nystatin-Triamcinolone | 25 | $1,898 | $76 |
| Testosterone Cypionate | 38 | $1,608 | $42 |
| Oxybutynin Chloride | 29 | $1,096 | $38 |
| Cefuroxime | 47 | $804 | $17 |
| Pentoxifylline | 19 | $767 | $40 |
| Doxazosin Mesylate | 17 | $666 | $39 |
| Tramadol | 100 | $311 | $3 |
| Sulfamethoxazole-Trimethoprim | 48 | $282 | $6 |
| Terazosin | 14 | $201 | $14 |
| Allopurinol | 16 | $178 | $11 |
| Alprazolam | 12 | $74 | $6 |
| Hydrocodone-Acetaminophen | 20 | $66 | $3 |
| Meloxicam | 23 | $48 | $2 |
| Zolpidem | 13 | $47 | $4 |
| Lorazepam | 21 | $23 | $1 |
2018: 28 drugs
| Myrbetriq | 78 | $46,029 | $590 |
| Toviaz | 72 | $29,766 | $413 |
| Lupron Depot | 12 | $24,360 | $2,030 |
| Vesicare | 64 | $18,479 | $289 |
| Rapaflo | 30 | $16,961 | $565 |
| Tamsulosin | 672 | $13,988 | $21 |
| Alfuzosin Hcl Er | 238 | $8,633 | $36 |
| Dutasteride | 105 | $6,396 | $61 |
| Cialis | 18 | $6,389 | $355 |
| Testosterone | 14 | $4,825 | $345 |
| Finasteride | 212 | $4,649 | $22 |
| Nitrofurantoin Mono-Macro | 97 | $4,034 | $42 |
| Bethanechol Chloride | 46 | $3,443 | $75 |
| Potassium Citrate Er | 29 | $2,498 | $86 |
| Ciprofloxacin | 333 | $2,159 | $6 |
| Testosterone Cypionate | 52 | $2,067 | $40 |
| Bicalutamide | 49 | $1,772 | $36 |
| Cefuroxime | 53 | $1,198 | $23 |
| Oxybutynin Chloride | 24 | $716 | $30 |
| Oxybutynin Chloride Er | 16 | $692 | $43 |
| Terazosin | 11 | $238 | $22 |
| Sulfamethoxazole-Trimethoprim | 34 | $181 | $5 |
| Levofloxacin | 16 | $180 | $11 |
| Tramadol | 62 | $165 | $3 |
| Azithromycin | 18 | $142 | $8 |
| Alprazolam | 11 | $68 | $6 |
| Zolpidem | 13 | $36 | $3 |
| Lorazepam | 19 | $20 | $1 |
2017: 28 drugs
| Myrbetriq | 72 | $34,483 | $479 |
| Rapaflo | 26 | $11,500 | $442 |
| Tamsulosin | 491 | $10,629 | $22 |
| Toviaz | 30 | $9,900 | $330 |
| Cialis | 23 | $9,606 | $418 |
| Vesicare | 26 | $9,455 | $364 |
| Androgel | 12 | $6,776 | $565 |
| Alfuzosin Hcl Er | 224 | $6,179 | $28 |
| Dutasteride | 57 | $4,822 | $85 |
| Nitrofurantoin Mono-Macro | 62 | $3,116 | $50 |
| Finasteride | 159 | $3,102 | $20 |
| Bethanechol Chloride | 39 | $2,141 | $55 |
| Testosterone Cypionate | 51 | $2,053 | $40 |
| Valacyclovir | 17 | $1,620 | $95 |
| Potassium Citrate Er | 18 | $1,293 | $72 |
| Ciprofloxacin | 194 | $1,229 | $6 |
| Bicalutamide | 32 | $1,199 | $37 |
| Cefuroxime | 27 | $639 | $24 |
| Oxybutynin Chloride | 15 | $575 | $38 |
| Doxazosin Mesylate | 11 | $545 | $50 |
| Allopurinol | 15 | $328 | $22 |
| Levofloxacin | 37 | $275 | $7 |
| Terazosin | 14 | $274 | $20 |
| Tramadol | 71 | $238 | $3 |
| Sulfamethoxazole-Trimethoprim | 26 | $161 | $6 |
| Azithromycin | 16 | $138 | $9 |
| Escitalopram | 12 | $64 | $5 |
| Hydrochlorothiazide | 11 | $29 | $3 |
2016: 28 drugs
| Rapaflo | 49 | $17,253 | $352 |
| Toviaz | 49 | $14,423 | $294 |
| Tamsulosin | 465 | $11,009 | $24 |
| Myrbetriq | 24 | $10,737 | $447 |
| Androgel | 17 | $8,577 | $505 |
| Vesicare | 26 | $7,532 | $290 |
| Avodart | 21 | $7,235 | $345 |
| Cialis | 21 | $6,304 | $300 |
| Dutasteride | 58 | $5,965 | $103 |
| Alfuzosin Hcl Er | 163 | $4,213 | $26 |
| Bethanechol Chloride | 69 | $3,949 | $57 |
| Nitrofurantoin Mono-Macro | 60 | $2,569 | $43 |
| Finasteride | 152 | $2,568 | $17 |
| Nystatin-Triamcinolone | 11 | $1,901 | $173 |
| Levofloxacin | 241 | $1,891 | $8 |
| Potassium Citrate Er | 19 | $1,029 | $54 |
| Doxazosin Mesylate | 21 | $969 | $46 |
| Cefuroxime | 24 | $793 | $33 |
| Ciprofloxacin | 81 | $671 | $8 |
| Bicalutamide | 13 | $509 | $39 |
| Allopurinol | 19 | $405 | $21 |
| Terazosin | 15 | $327 | $22 |
| Hydrocodone-Acetaminophen | 21 | $201 | $10 |
| Tramadol | 71 | $197 | $3 |
| Sulfamethoxazole-Trimethoprim | 23 | $121 | $5 |
| Escitalopram | 12 | $60 | $5 |
| Hydrochlorothiazide | 15 | $39 | $3 |
| Meloxicam | 11 | $26 | $2 |
2015: 28 drugs
| Avodart | 135 | $27,919 | $207 |
| Toviaz | 79 | $20,639 | $261 |
| Rapaflo | 57 | $13,142 | $231 |
| Tamsulosin | 399 | $12,969 | $33 |
| Androgel | 19 | $10,276 | $541 |
| Vesicare | 44 | $10,090 | $229 |
| Jalyn | 26 | $6,932 | $267 |
| Myrbetriq | 12 | $5,268 | $439 |
| Bethanechol Chloride | 59 | $3,442 | $58 |
| Alfuzosin Hcl Er | 171 | $3,222 | $19 |
| Cialis | 13 | $3,113 | $239 |
| Nystatin-Triamcinolone | 13 | $2,345 | $180 |
| Finasteride | 159 | $2,047 | $13 |
| Phenazopyridine | 30 | $2,010 | $67 |
| Nitrofurantoin Mono-Macro | 43 | $1,739 | $40 |
| Ciprofloxacin | 271 | $1,629 | $6 |
| Cefuroxime | 39 | $1,466 | $38 |
| Doxazosin Mesylate | 20 | $1,047 | $52 |
| Bicalutamide | 25 | $783 | $31 |
| Allopurinol | 18 | $284 | $16 |
| Terazosin | 23 | $283 | $12 |
| Oxybutynin Chloride | 11 | $279 | $25 |
| Sulfamethoxazole-Trimethoprim | 30 | $231 | $8 |
| Tramadol | 42 | $137 | $3 |
| Escitalopram | 12 | $76 | $6 |
| Lorazepam | 20 | $69 | $3 |
| Sertraline | 11 | $68 | $6 |
| Meloxicam | 20 | $53 | $3 |
2014: 27 drugs
| Avodart | 147 | $28,492 | $194 |
| Vesicare | 79 | $18,157 | $230 |
| Androgel | 43 | $17,829 | $415 |
| Jalyn | 70 | $15,383 | $220 |
| Toviaz | 68 | $13,863 | $204 |
| Rapaflo | 62 | $11,465 | $185 |
| Tamsulosin | 349 | $7,463 | $21 |
| Myrbetriq | 19 | $6,669 | $351 |
| Axiron | 12 | $5,688 | $474 |
| Nystatin-Triamcinolone | 24 | $4,379 | $182 |
| Alfuzosin Hcl Er | 130 | $3,561 | $27 |
| Nitrofurantoin Mono-Macro | 53 | $2,989 | $56 |
| Bicalutamide | 35 | $1,639 | $47 |
| Quetiapine | 12 | $1,636 | $136 |
| Finasteride | 76 | $1,593 | $21 |
| Ciprofloxacin | 275 | $1,586 | $6 |
| Doxazosin Mesylate | 37 | $1,564 | $42 |
| Oxybutynin Chloride | 37 | $1,289 | $35 |
| Bethanechol Chloride | 30 | $1,264 | $42 |
| Cefuroxime | 19 | $641 | $34 |
| Hydrocodone-Acetaminophen | 43 | $288 | $7 |
| Sulfamethoxazole-Trimethoprim | 28 | $235 | $8 |
| Terazosin | 25 | $198 | $8 |
| Phenazopyridine | 14 | $174 | $12 |
| Sertraline | 16 | $114 | $7 |
| Lorazepam | 20 | $57 | $3 |
| Ibuprofen | 11 | $55 | $5 |
2013: 32 drugs
| Vesicare | 118 | $29,034 | $246 |
| Avodart | 137 | $25,222 | $184 |
| Androgel | 65 | $23,458 | $361 |
| Jalyn | 85 | $16,306 | $192 |
| Testim | 19 | $8,832 | $465 |
| Rapaflo | 42 | $8,245 | $196 |
| Elmiron | 12 | $8,118 | $676 |
| Tamsulosin | 327 | $7,432 | $23 |
| Toviaz | 29 | $5,058 | $174 |
| Alfuzosin | 104 | $4,494 | $43 |
| Fortesta | 12 | $4,151 | $346 |
| Nitrofurantoin Mono-Macro | 52 | $3,476 | $67 |
| Nystatin-Triamcinolone | 19 | $2,922 | $154 |
| Quetiapine | 12 | $2,350 | $196 |
| Finasteride | 72 | $2,304 | $32 |
| Ciprofloxacin | 290 | $1,827 | $6 |
| Bicalutamide | 32 | $1,686 | $53 |
| Bethanechol Chloride | 25 | $1,169 | $47 |
| Atorvastatin | 11 | $770 | $70 |
| Doxazosin Mesylate | 30 | $655 | $22 |
| Hydrocodone-Acetaminophen | 65 | $512 | $8 |
| Oxybutynin Chloride | 17 | $484 | $28 |
| Cefuroxime | 26 | $356 | $14 |
| Terazosin | 32 | $303 | $9 |
| Sulfamethoxazole-Trimethoprim | 35 | $254 | $7 |
| Phenazopyridine | 31 | $220 | $7 |
| Levofloxacin | 23 | $158 | $7 |
| Sertraline | 16 | $130 | $8 |
| Meloxicam | 15 | $103 | $7 |
| Atenolol | 12 | $95 | $8 |
| Lorazepam | 23 | $73 | $3 |
| Zolpidem | 14 | $49 | $4 |
Money from drug and device companies
$222 in 2025
| 2025 | 3 | 4 | None | $222 |
| 2024 | 4 | 5 | None | $115 |
| 2023 | 5 | 5 | None | $95 |
| 2022 | 5 | 5 | None | $184 |
| 2021 | 5 | 6 | None | $175 |
| 2020 | 1 | 1 | None | $22 |
| 2019 | 5 | 11 | None | $479 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Teleflex | Urolift | $191 | 2 payments
|
| Coloplast | Coloplast Tfl Drive | $16 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $14 | 1 payment
|
See all 4 published payments
| Teleflex | Meals · 2025-12-03 | Urolift | $155 |
| Coloplast | Meals · 2025-09-18 | Coloplast Tfl Drive | $16 |
| Teleflex | Meals · 2025-07-08 | Urolift | $36 |
| Sumitomo Pharma America | Meals · 2025-02-04 | Orgovyx | $14 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $115
| Sumitomo Pharma America | Gemtesa | $50 | 2 payments
|
| PROCEPT BioRobotics | Aquabeam System | $27 | 1 payment
|
| Abbvie | Lupron Depot | $23 | 1 payment
|
| Tolmar | Eligard | $16 | 1 payment
|
2023: $95
| UroGen Pharma | Jelmyto | $28 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $24 | 1 payment
|
| AbbVie | Lupron Depot | $16 | 1 payment
|
| Myriad Genetic Laboratories | None | $14 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $13 | 1 payment
|
2022: $184
| Astellas Pharma US | None | $90 | 1 payment
|
| Teleflex | Urolift | $40 | 1 payment
|
| Pfizer | Xtandi | $23 | 1 payment
|
| Axonics | Axonics | $17 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $14 | 1 payment
|
2021: $175
| Teleflex | Urolift System | $57 | 1 payment
|
| Pfizer | Xtandi | $52 | 2 payments
|
| Acerus Pharmaceuticals | Natesto | $25 | 1 payment
|
| Myovant Sciences | Orgovyx | $24 | 1 payment
|
| Medtronic | Interstim | $17 | 1 payment
|
2020: $22
| Baxter Healthcare | Tisseel | $22 | 1 payment
|
2019: $479
| Astellas Pharma US | Xtandi | $167 | 7 payments
|
| Teva Pharmaceuticals USA | Ajovy | $130 | 1 payment
|
| Coloplast | Altis | $115 | 1 payment
|
| Conmed | Airseal | $55 | 1 payment
|
| Pfizer | Xtandi | $13 | 1 payment
|
Professional record
- NPI
- 1922116698
- Licence
- CA A35822California A35822: Current · expires 2028-01-31
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00A35822
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- 1360 W 6th St Ste 160, San Pedro, CA, 90732
- NPI first listed
- 2006-08-25
- NPI last updated
- 2008-11-21
This is when the NPI record was last certified, not a medical board exam.